Valbenazine (INGREZZA)
Tardive Dyskinesia
Key Facts
About Neurocrine Biosciences
Neurocrine Biosciences has successfully transitioned from a discovery-focused entity to a fully integrated commercial leader in neuroscience. Its mission is to relieve suffering through brave science, exemplified by the blockbuster success of INGREZZA for tardive dyskinesia and a growing portfolio in movement disorders and endocrinology. The company's strategy leverages deep neurobiological expertise to advance a diversified pipeline, pursue strategic collaborations, and expand the labels of its commercial assets to drive sustainable growth.
View full company profileAbout Neurocrine Biosciences
Neurocrine Biosciences has successfully transitioned from a discovery-focused entity to a fully integrated commercial leader in neuroscience. Its mission is to relieve suffering through brave science, exemplified by the blockbuster success of INGREZZA for tardive dyskinesia and a growing portfolio in movement disorders and endocrinology. The company's strategy leverages deep neurobiological expertise to advance a diversified pipeline, pursue strategic collaborations, and expand the labels of its commercial assets to drive sustainable growth.
View full company profileAbout Neurocrine Biosciences
Neurocrine Biosciences has successfully transitioned from a discovery-focused entity to a fully integrated commercial leader in neuroscience. Its mission is to relieve suffering through brave science, exemplified by the blockbuster success of INGREZZA for tardive dyskinesia and a growing portfolio in movement disorders and endocrinology. The company's strategy leverages deep neurobiological expertise to advance a diversified pipeline, pursue strategic collaborations, and expand the labels of its commercial assets to drive sustainable growth.
View full company profileTherapeutic Areas
Other Tardive Dyskinesia Drugs
| Drug | Company | Phase |
|---|---|---|
| SOM3355 | SOM Biotech | Phase 2a PoC |
| Tardive Dyskinesia Program | Medicure | Unknown |